Unveiling the Secrets to Quality: A Deep Dive into the Week of Quality 2024 (2026)

Unveiling the Secrets of Quality Assurance: A Comprehensive Guide to Medicines, Vaccines, and In Vitro Diagnostics

Are you ready to dive into the world of quality assurance for healthcare products? Let's explore how we can ensure the safety and efficacy of medicines, vaccines, and in vitro diagnostics (IVDs) through a global training initiative.

In the realm of healthcare, quality is paramount. Ensuring the safety and efficacy of medicines, vaccines, and IVDs is crucial for public health. However, manufacturers in low- and middle-income countries (LMICs) often face challenges in achieving quality in local production. These challenges include a lack of a skilled workforce trained in quality standards and regulatory guidelines, as well as difficulties in implementing a quality culture within manufacturing facilities.

To address these issues, the Local Production and Assistance (LPA) Unit within the Innovation and Emerging Technologies Department (IET) at the World Health Organization (WHO) has taken a proactive approach. The LPA Unit supports Member States, particularly LMICs, in strengthening sustainable local production and technology transfer to improve access to essential medical products. Their holistic approach involves conducting ecosystem assessments, developing strategies and roadmaps, providing comprehensive capacity-building and technical assistance, and facilitating technology transfer.

One of the key initiatives is the Week of Quality, a global training event designed to complement the annual Virtual cGMP Training Marathons. The first Week of Quality, held from June 16-20, 2023, focused on establishing quality specifications for vaccines, medicines, and IVDs based on WHO and international guidelines. This was a crucial step towards achieving quality assurance.

The second Week of Quality, taking place from April 15 to June 13, 2024, delves deeper into the regulatory compliance aspects of medicines, IVDs, vaccines, and biotherapeutics. Over 1700 vaccine and biopharmaceutical manufacturers and regulators attended the sessions, gaining insights into key aspects of regulatory compliance. Additionally, more than 1400 pharmaceutical manufacturers and regulators enhanced their knowledge of quality requirements for pharmaceutical product development.

For the first time, over 1000 IVD manufacturers and regulators participated, building capacity in design, quality, and compliance principles to optimize IVD product development. The training material, compiled from questions raised by manufacturers and regulators during the second Week of Quality, includes questions-and-answers (Q&A) with answers prepared and peer-reviewed by experts with extensive experience in the vaccine, medicine, or IVD industry, as well as national regulatory authorities and other organizations.

This resource serves as a continuous learning tool for manufacturers and stakeholders, providing a reference document to acquire and strengthen knowledge and capacities in local production of quality vaccines, medicines, and IVDs. By addressing the challenges of quality assurance, we can ensure that essential medical products are accessible, safe, and effective for all.